Completed PHASE1 INTERVENTIONAL 1-arm NCT01551329

Ketamine for Depression and Alcohol Dependence (KetamineDep)

A Randomized Controlled Trial of the N-methyl-D-aspartate (NMDA) Receptor Antagonist Ketamine in Comorbid Depression and Alcohol Dependence.

Sponsor: VA Connecticut Healthcare System

Conditions Alcohol Dependence Depression

Interventions Ketalar (ketamine)

Updated 6 times since 2017 Last updated: Mar 5, 2020 Started: Mar 31, 2012 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01551329, this PHASE1 trial focuses on Alcohol Dependence and Depression and remains completed. Sponsored by VA Connecticut Healthcare System, it has been updated 6 times since 2012, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Apr 2020 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

VA Connecticut Healthcare System
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• West Haven, United States